Successful therapy with biologic agents in early and established RA has been associated with decreases in circulating ACPA and pro-inflammatory cytokine levels though not always correlating with clinical indices of disease activity [2–13]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.